Glatiramer Acetate
- 1 August 2010
- journal article
- review article
- Published by Springer Science and Business Media LLC in Drugs
- Vol. 70 (12), 1545-1577
- https://doi.org/10.2165/11204560-000000000-00000
Abstract
Glatiramer acetate is a synthetic analogue of the multiple sclerosis (MS)-associated antigen, myelin basic protein. It is indicated in the EU, US and many other countries to reduce the frequency of relapses in patients with relapsing-remitting MS (RRMS), and for the treatment of patients who have experienced a well defined first clinical episode and are at high risk of developing clinically definite MS or have features of MS on MRI. The efficacy of glatiramer acetate in patients with RRMS has been shown in two randomized, double-blind, multicentre phase III trials. In one trial, glatiramer acetate was associated with a significantly lower mean relapse rate than placebo after 24 months’ treatment (primary endpoint). In an ongoing open-label extension to this trial, glatiramer acetate was associated with a sustained reduction in the relapse rate at the 6-, 8- and 15-year follow-ups. In the other trial, the mean cumulative number of gadolinium-enhancing lesions on T1-weighted MRI images was significantly lower in glatiramer acetate versus placebo recipients after 9 months’ treatment (primary endpoint). Glatiramer acetate also had generally similar efficacy to subcutaneous interferon (IFN)-β-1a or IFNβ-1b in two large randomized, open-label, multicentre phase III trials conducted over 96 weeks or ≥2 years. These data were supported by those from a smaller randomized, open-label phase IV trial that utilized a unique imaging protocol to evaluate the efficacy of glatiramer acetate versus that of IFNβ-1b over ≥2 years. In these trials, there was no significant difference between glatiramer acetate and IFNβ recipients in any of the clinical endpoints at study end (e.g. time to first relapse [primary endpoint of the REGARD trial] or risk of relapse [primary endpoint of the BEYOND trial]). Moreover, there was no significant difference between glatiramer acetate and IFNβ-1b recipients in the median number of combined active lesions per patient per monthly MRI scan during the first 12 months of treatment (primary endpoint of the BECOME trial). In general, there was no significant between-group difference in the majority of other MRI-assessed endpoints in any of the trials. The efficacy of glatiramer acetate in patients with clinically isolated syndrome (CIS) was established in a randomized, double-blind, double-dummy, multicentre phase III trial (the PreCISe trial). In this study, glatiramer acetate was associated with a significantly longer time to conversion to clinically definite MS than placebo (primary endpoint). Glatiramer acetate was generally well tolerated in clinical trials, with most adverse events being mild to moderate in severity. Injection site-related reactions and immediate post-injection systemic reactions were the most frequently observed adverse events associated with glatiramer acetate in clinical studies. In conclusion, glatiramer acetate is a valuable first-line option in the treatment of RRMS, as well as being an option in the treatment of CIS.Keywords
This publication has 100 references indexed in Scilit:
- Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis [RETIRED]Neurology, 2010
- Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetateMultiple Sclerosis Journal, 2010
- Promoting oligodendrogenesis and myelin repair using the multiple sclerosis medication glatiramer acetateProceedings of the National Academy of Sciences of the United States of America, 2009
- Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1β in human monocytes and multiple sclerosisProceedings of the National Academy of Sciences of the United States of America, 2009
- GLANCENeurology, 2009
- Multiple sclerosisThe Lancet, 2008
- Demyelination arrest and remyelination induced by glatiramer acetate treatment of experimental autoimmune encephalomyelitisProceedings of the National Academy of Sciences of the United States of America, 2008
- Magnetic resonance imaging as a surrogate outcome for multiple sclerosis relapsesMultiple Sclerosis Journal, 2008
- Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosisHealth and Quality of Life Outcomes, 2008
- Rating neurologic impairment in multiple sclerosisNeurology, 1983